¼¼°èÀÇ ÁÖÀÔ ¿ä¹ý ±â±â ½ÃÀå
Infusion Therapy Devices
»óǰÄÚµå : 1794009
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 279 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,183,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,550,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ÁÖÀÔ ¿ä¹ý ±â±â ½ÃÀåÀº 2030³â±îÁö 695¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 450¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ÁÖÀÔ ¿ä¹ý ±â±â ½ÃÀåÀº 2024-2030³â¿¡ CAGR 7.5%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 695¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ÁÖÀÔ ÆßÇÁ´Â CAGR 8.9%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 452¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼Ò¸ðǰ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 5.0%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 123¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 12.0%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÁÖÀÔ ¿ä¹ý ±â±â ½ÃÀåÀº 2024³â¿¡ 123¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 149¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 12.0%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 3.7%¿Í 7.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 5.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ÁÖÀÔ ¿ä¹ý ±â±â ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¼ö¾× Ä¡·á Àåºñ°¡ ÀÓ»ó ÇöÀå¿¡¼­ Á¡Á¡ ´õ Áß¿äÇØÁö´Â ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¼ö¾× Ä¡·á Àåºñ´Â ¼ö¾×, Åõ¾à, ¿µ¾çÁ¦, Ç÷¾× Á¦Á¦ÀÇ °ü¸®, Á¤È®Çϰí Áö¼ÓÀûÀÎ Åõ¿©¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó º´¿ø ¹× ¿Ü·¡ ȯÀÚ È¯°æ¿¡¼­ ¼ö¾× Ä¡·á Àåºñ´Â Çö´ë ÀÇ·á¿¡ ¾ø¾î¼­´Â ¾È µÉ Çʼö ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ÀÌ ÀåºñµéÀº ¾Ï, °¨¿°, Å»¼ö, ¸¸¼ºÅëÁõ, ÀÚ°¡¸é¿ªÁúȯ µî ´Ù¾çÇÑ Áõ»ó¿¡ ´ëÇÑ ¼ö¾×¿ä¹ýÀ» ½ÃÇàÇÏ´Â µ¥ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÕ´Ï´Ù. º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ÀçÅà °£È£ »ç¾÷ÀÚ´Â ÀϰüµÈ Åõ¾à°ú ȯÀÚÀÇ ¾ÈÀüÀ» º¸ÀåÇϱâ À§ÇØ ÁÖÀÔ ÆßÇÁ, ÁÖÀÔ ¼¼Æ®, Ä«Å×ÅÍ¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ °í·ÉÈ­¿Í ÀÌ¿¡ µû¸¥ ´ç´¢º´, ½ÉÇ÷°üÁúȯ, ¾Ï µî ¸¸¼ºÁúȯ Áõ°¡·Î Àå±âÀûÀ̰í ÀçÅÃÀûÀÎ ¼ö¾×¿ä¹ýÀÇ Çʿ伺ÀÌ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼´Â ÀÇ·á ½Ã½ºÅÛÀÌ ±Þ¼º±â ÀÔ¿ø Ä¡·á¿¡¼­ º¸´Ù À¯¿¬Çϰí ȯÀÚ Áß½ÉÀÇ ÀÇ·á Á¦°ø ¸ðµ¨·Î ÀüȯÇÏ´Â °ÍÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ½Å¼ÓÇϰí Á¤È®ÇÑ ¾à¹°Àü´ÞÀÌ »ý»ç¸¦ °¡¸£´Â Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¼ö¾×±â´Â ÁßȯÀÚ Ä¡·á¿Í ÀÀ±ÞÀÇ·á¿¡¼­µµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¼Ò¾Æ°ú³ª ½Å»ý¾Æ º´µ¿¿¡¼­´Â ¼Ò·®, °í°¨µµ Åõ¿©¿¡ ´ëÀÀÇÒ ¼ö Àִ Ư¼ö ¼³°èµÈ ÁÖÀÔ ½Ã½ºÅÛÀÌ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ »ý¹°Á¦Á¦ ¹× Ư¼ö ÀǾàǰÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ±× Áß »ó´ç¼ö´Â Àå±â°£ÀÇ Á¤¸Æ ¶Ç´Â ÇÇÇÏ Åõ¿©°¡ ÇÊ¿äÇϹǷΠ¼ö¾× ÀåÄ¡ÀÇ Ä¡·á ¹üÀ§°¡ È®´ëµÇ°í ÀÖ½À´Ï´Ù. °¡Ä¡ ±â¹Ý Áø·á ¸ðµ¨°ú º´¿ø ÀçÀÔ¿ø Æä³ÎƼÀÇ µîÀåÀ¸·Î ¾ÈÀüÇϰí È¿°úÀûÀÎ ¿Ü·¡ ¼ö¾×À» È®º¸ÇÏ´Â °Íµµ ºñ¿ë Àý°¨ Àü·«ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇյǾî Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛ¿¡¼­ ¼ö¾× Ä¡·á Àåºñ°¡ Ä¡·á °ü¸®ÀÇ ±Ù°£À¸·Î ±× Á߿伺ÀÌ È®´ëµÇ°í ÀÖÀ½À» ÀÔÁõÇϰí ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀÌ ¼ö¾× ¿ä¹ýÀÇ ¾ÈÀü¼º°ú È¿À²¼ºÀ» Çâ»ó½Ãų ¼ö Àִ°¡?

±â¼ú Çõ½ÅÀº ¼ö¾× Ä¡·á ÀåºñÀÇ µðÀÚÀΰú ±â´É¿¡ Çõ¸íÀ» ÀÏÀ¸ÄÑ ÀÓ»óÀÇ¿Í È¯ÀÚ ¸ðµÎ¿¡°Ô ´õ ¾ÈÀüÇϰí, ´õ Á¤È®Çϰí, ´õ ½±°Ô »ç¿ëÇÒ ¼ö ÀÖµµ·Ï Çϰí ÀÖ½À´Ï´Ù. ±âÁ¸ÀÇ ÁÖÀÔ ÆßÇÁ´Â ½Ç½Ã°£ ¸ð´ÏÅ͸µ, µ¥ÀÌÅÍ ·Î±ë, º´¿ø Á¤º¸ ½Ã½ºÅÛ°úÀÇ ÅëÇÕÀÌ °¡´ÉÇÑ ½º¸¶Æ® µð¹ÙÀ̽º·Î ÁøÈ­Çß½À´Ï´Ù. ÃֽŠÁÖÀÔ ÆßÇÁ¿¡´Â À߸øµÈ ÇÁ·Î±×·¡¹ÖÀ» ¹æÁöÇϰí Åõ¾à ¿À·ùÀÇ À§ÇèÀ» ÁÙÀÌ´Â µ¥ µµ¿òÀÌ µÇ´Â Åõ¾à ¿À·ù °¨¼Ò ½Ã½ºÅÛ(DERS)ÀÌ ÀåÂøµÇ¾î ÀÖ½À´Ï´Ù. ÀÌ ½º¸¶Æ® ÆßÇÁ¿¡´Â ¾à¹° ¶óÀ̺귯¸®°¡ ³»ÀåµÇ¾î ÀÖÀ¸¸ç, ó¹æµÈ ¿ë·® ¸Å°³º¯¼ö¿¡¼­ ¹þ¾î³­ °æ¿ì °£È£»ç³ª ¾à»ç¿¡°Ô ¾Ë·ÁÁÖ´Â °æ°í ½Ã½ºÅÛÀ» °®Ãß°í ÀÖÀ¸¸ç, ȯÀÚÀÇ ¾ÈÀü¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. ¹«¼± ¿¬°áÀ» ÅëÇØ ¿ø°Ý ¸ð´ÏÅ͸µ ¹× ÀüÀڰǰ­±â·Ï¿¡ ÀÚµ¿ ±â·ÏÀÌ °¡´ÉÇÏ¿© ÀÇ·áÁøÀÇ °ü¸® ºÎ´ãÀ» ÁÙÀÌ°í ¼ö¾× °ü·Ã ÁöÇ¥¸¦ ´õ Àß ÃßÀûÇÒ ¼ö ÀÖ½À´Ï´Ù. ÈÞ´ë¿ë ¹× ¿þ¾î·¯ºí ¼ö¾× ÀåÄ¡µµ ´«¿¡ ¶ç°Ô ¹ßÀüÇÏ¿© ÀçÅà ¹× ¿Ü·¡¿¡¼­ Áö¼ÓÀûÀÎ Ä¡·á°¡ ÇÊ¿äÇÑ È¯ÀÚµéÀÇ À̵¿¼ºÀ» ³ô¿©ÁÖ°í ÀÖ½À´Ï´Ù. ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º°øÇÐ ¹× ¼¾¼­ ÅëÇÕÀÇ Çõ½ÅÀº üÁß, ü¾× ±ÕÇü µî ȯÀÚº° º¯¼ö¿¡ µû¶ó ÀÚµ¿À¸·Î À¯·®À» Á¶ÀýÇÏ´Â ¼ö¾× ÁÖÀÔ ½Ã½ºÅÛÀÇ °³¹ß·Î À̾îÁö°í ÀÖ½À´Ï´Ù. ¹èÅ͸® ±â¼úÀÇ Çâ»óÀ¸·Î ÀÛµ¿ ½Ã°£ÀÌ ±æ¾îÁö°í, ´õ ÄÄÆÑÆ®ÇÑ ÆûÆÑÅͰ¡ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ Àç·á °úÇÐÀÇ ¹ßÀüÀ¸·Î ³»±¸¼ºÀÌ ³ô°í »ýü ÀûÇÕ¼ºÀÌ ³ôÀº Ä«Å×ÅÍ ¶óÀÎÀÌ Á¦Á¶µÇ¾î °¨¿° ¹× ºÎÀÛ¿ëÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀΰøÁö´ÉÀº ¼ö¾× Ä¡·á¿¡µµ ¿µÇâÀ» ¹ÌÄ¡±â ½ÃÀÛÇßÀ¸¸ç, ¿¹Ãø ¾Ë°í¸®ÁòÀº Æó»ö ¹× °ø±â ÀζóÀÎ »ç°í¿Í °°Àº ÀáÀçÀû ÇÕº´ÁõÀ» »çÀü¿¡ ½Äº°ÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áö¼ÓÀûÀÎ °³¼±Àº ¼ö¾× Ä¡·á ÀåºñÀÇ ±â¼úÀû ¼º´É»Ó¸¸ ¾Æ´Ï¶ó Àüü ÀÓ»ó ¿öÅ©Ç÷ο츦 °­È­ÇÏ¿© º¸´Ù È¿À²ÀûÀÌ°í ¸ÂÃã Ä¡·á¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

¼ö¾× ÀåÄ¡ÀÇ ¸ÂÃãÈ­¿Í »ç¿ëÀº ´Ù¾çÇÑ ÀÇ·á Àü¹® ºÐ¾ß¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¡´Â°¡?

¼ö¾× Ä¡·á ±â±â ½ÃÀåÀº ³ôÀº Àü¹®¼ºÀ» Ư¡À¸·Î Çϸç, °¢ ÀÇ·á ºÐ¾ß´Â °¢°¢ÀÇ ÀÓ»ó ¿ëµµ¿¡ ¸Â´Â °íÀ¯ÇÑ ±â´É°ú ¼º´É ±âÁØÀ» ¿ä±¸ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î ¾Ï ¿µ¿ª¿¡¼­ ÁÖÀÔ ÀåÄ¡´Â Á¤È®ÇÑ Åõ¿© ½ºÄÉÁÙÀ» ¼ö¹ÝÇÏ´Â º¹ÀâÇÑ È­Çпä¹ý ¿ä¹ýÀ̳ª ÀÇ·áÁøÀ» º¸È£Çϱâ À§ÇØ Æ¯º°ÇÑ ¾ÈÀü ±â´ÉÀ» ÇÊ¿ä·Î ÇÏ´Â ¼¼Æ÷µ¶¼º ¾à¹°ÀÇ Àü´Þ¿¡ ´ëÀÀÇØ¾ß ÇÕ´Ï´Ù. Àü¿°º´ °ü¸®, ƯÈ÷ Áý´Ü °¨¿° ¹× Àü¿°º´ ¹ß»ý½Ã ÁÖÀÔ ÆßÇÁ´Â Ç×»ýÁ¦, Ç×¹ÙÀÌ·¯½ºÁ¦, ¼öÈ­¾×ÀÇ ½Å¼ÓÇÑ ¹èÄ¡ ¹× ´ë·® »ç¿ë¿¡ ´ëÀÀÇØ¾ß ÇÕ´Ï´Ù. ¼ö¼ú ¹× ¿ÏÈ­ Ä¡·áÀÇ ÅëÁõ °ü¸® ÇÁ·ÎÅäÄÝÀº Á¾Á¾ ȯÀÚ °ü¸® ÁøÅëÁ¦(PCA) ÆßÇÁ¿¡ ÀÇÁ¸ÇÏ¿© ¾ÈÀüÇÑ ¸Å°³ º¯¼ö ³»¿¡¼­ ó¹æµÈ ¾çÀÇ ÁøÅëÁ¦¸¦ ÀÚ°¡ Åõ¿©ÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ÁßȯÀڽǰú ½Å»ý¾Æ º´µ¿¿¡¼­ ¼ö¾× ÁÖÀÔ ÀåÄ¡´Â ¼Ò·®, °íÁ¤¹Ð Åõ¿©, ¶§·Î´Â ¸¶ÀÌÅ©·Î ¸®ÅÍ ¼öÁرîÁö ´ëÀÀÇØ¾ß Çϸç, ÷´Ü °æº¸ ¹× ÆäÀÏ ¼¼ÀÌÇÁ ±â´ÉÀ» °®Ãß¾î¾ß ÇÕ´Ï´Ù. ¼øÈ¯±âº´µ¿¿¡¼­´Â Ç÷°ü¾Ð¹ÚÁ¦, °­½ÉÁ¦, Ç×ÀÀ°íÁ¦ µîÀÇ ¼ö¾×¿ä¹ýÀ» ½ÃÇàÇϰí ÀÖÀ¸¸ç, ¸ðµÎ ½Ç½Ã°£ ¸ð´ÏÅ͸µ°ú ¾ÈÁ¤ÀûÀÎ ¼Óµµ Á¦¾î°¡ ¿ä±¸µË´Ï´Ù. ÀçÅÃÄ¡·á¿¡¼­´Â È޴뼺, Æí¸®¼º, Á÷°üÀûÀÎ ÀÎÅÍÆäÀ̽º°¡ Áß¿ä½ÃµÇ°í ÀÖ½À´Ï´Ù. µ¿¹° ÀÇ·á¿¡¼­µµ ´Ù¾çÇÑ Å©±âÀÇ µ¿¹°¿¡ ¸Â°Ô ¼³°èµÈ ÁÖÀÔ ÆßÇÁ°¡ »ç¿ëµÇ°í ÀÖÀ¸¸ç, ½ÃÀåÀÇ ÆøÀÌ ³Ð´Ù´Â °ÍÀ» ¾Ë ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÓ»óÀû ´Ù¾ç¼ºÀ¸·Î ÀÎÇØ °¢ Á¦Á¶¾÷üµéÀº Á¤·® ÆßÇÁ¿Í ÁÖ»ç±â ÆßÇÁºÎÅÍ ¿¤¶ó½ºÅä¸Ó ¹× ÀÓÇöõÆ® ½Ã½ºÅÛ±îÁö ´Ù¾çÇÑ ±â±â °³¹ß¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦ Áؼö, »ç¿ëÀÚ ±³À°, ´Ù¾çÇÑ ¼ö¾× ¼¼Æ®¿ÍÀÇ È£È¯¼º ¶ÇÇÑ ÀÇ·á ºÐ¾ß¿¡ µû¶ó ´Ù¸£¸ç, ¼³°è ¿ì¼±¼øÀ§¿Í ±¸¸Å ÀÇ»ç°áÁ¤¿¡ ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ±× °á°ú, ½ÃÀå »óȲÀº °íµµ·Î ¼¼ºÐÈ­µÇ¾î ¸ÂÃãÇü, ¾ÈÀü¼º, »ç¿ë ÆíÀǼºÀÌ Á¦Ç° Â÷º°È­¿Í ÀÓ»ó äÅÃÀÇ Áß½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¼¼°è ¼ö¾×Ä¡·á±â ½ÃÀåÀÇ ±Þ¼ºÀå ¿øµ¿·ÂÀº?

¼ö¾× Ä¡·á ±â±â ½ÃÀåÀÇ ¼ºÀåÀº Àα¸ µ¿Çâ, ±â¼ú ¹ßÀü, ÀÇ·á °³Çõ, ¸¸¼ºÁúȯ ºÎ´ã Áõ°¡ µî ¿©·¯ °¡Áö º¹ÇÕÀûÀÎ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °¡Àå Áß¿äÇÑ ÃËÁø¿äÀÎ Áß Çϳª´Â Àü ¼¼°è¿¡¼­ °í·ÉÈ­ Àα¸°¡ Áõ°¡Çϸ鼭 Àå±âÀûÀÌ°í ºó¹øÇÑ ¼ö¾× ¿ä¹ýÀ» ÇÊ¿ä·Î ÇÏ´Â ¿©·¯ ¸¸¼ºÁúȯ¿¡ °É¸®±â ½¬¿öÁ³½À´Ï´Ù´Â Á¡ÀÔ´Ï´Ù. ¾Ï, ´ç´¢º´, ÀÚ°¡¸é¿ªÁúȯ, ½ÉÇ÷°üÁúȯ µîÀÇ À¯º´·ü È®´ë´Â Áö¼ÓÀû ÀÌ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ¾à¹° Åõ¿©ÀÇ Çʿ伺À» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼­ ¿Ü·¡ Ä¡·á¿Í ÀçÅÃÄ¡·á·ÎÀÇ ÀüȯÀº ȯÀÚ°¡ Àå±â°£ ÀÔ¿øÇÏÁö ¾Ê°íµµ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ´Â ÈÞ´ë¿ë ÁÖÀÔ ½Ã½ºÅÛÀÇ °³¹ß ¹× äÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ º´¿ø ¹× Ŭ¸®´Ð °ü¸®ÀÚ´Â ¿öÅ©Ç÷ο츦 °£¼ÒÈ­Çϰí, ÀÎÀû ¿À·ù¸¦ ÁÙÀ̸ç, ±ÔÁ¦ ±âÁØÀ» ÃæÁ·Çϰí, ȯÀÚ °á°ú¸¦ °³¼±Çϱâ À§ÇØ ÀüÀÚ ¹®¼­È­¸¦ Áö¿øÇÏ´Â ¼ö¾× ÁÖÀÔ ¼Ö·ç¼ÇÀ» ã°í ÀÖ½À´Ï´Ù. ƯÈ÷ ½ÅÈï ±¹°¡¿¡¼­´Â ÇコÄɾî ÀÎÇÁ¶ó¿¡ ´ëÇÑ Á¤ºÎ ÅõÀÚ°¡ ¼ö¾×±â±âÀÇ »õ·Î¿î ½ÃÀåÀ» °³¹ßÇÏ°í ´ë·® ÆÇ¸Å¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. COVID-19 ÆÒµ¥¹Í°ú °°Àº °øÁߺ¸°Ç ºñ»ó»çÅ´ ÁßȯÀÚ½Ç È¯°æ¿¡¼­ ´Ù¼öÀÇ È¯ÀÚ¸¦ Ä¡·áÇϱâ À§ÇØ È®Àå °¡´ÉÇÏ°í ½Å¼ÓÇÏ°Ô ¹èÆ÷ÇÒ ¼ö ÀÖ´Â ¼ö¾× ¼Ö·ç¼ÇÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¸¹Àº ±¹°¡ÀÇ Áø·áºñ ÁöºÒÁ¦µµ °³ÇõÀº Á¤È®ÇÑ ¾à¹° Åõ¿©¿Í ºÎÀÛ¿ë ȸÇǰ¡ ÀÇ·á ÇÁ·Î¹ÙÀÌ´õÀÇ º¸»ó¿¡ Á÷Á¢ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡´Â °¡Ä¡ ±â¹Ý ÀǷḦ Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ±â¼ú ±â¾÷°ú ÀÇ·á±â±â ±â¾÷ÀÇ Àü·«Àû Á¦ÈÞµµ Çõ½ÅÀÇ ¼Óµµ¸¦ °¡¼ÓÈ­Çϰí ÀÖÀ¸¸ç, ÇコÄɾîÀÇ ±¤¹üÀ§ÇÑ µðÁöÅÐ Àüȯ¿¡ µû¶ó ½º¸¶Æ® ±â´ÉÀ» µµÀÔÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÃËÁø¿äÀεéÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© ¼ö¾× Ä¡·á ±â±â ½ÃÀåÀº ±Þ¼ÓÇÑ ¼ºÀåÀ» À§ÇÑ ºñ¿ÁÇÑ È¯°æÀÌ Á¶¼ºµÇ°í ÀÖÀ¸¸ç, Àü ¼¼°è¿¡¼­ ±â¼ú °íµµÈ­, Á¢±Ù¼º È®´ë, ÀÓ»óÀû À¯¿ë¼º È®´ë°¡ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç°(ÁÖÀÔ ÆßÇÁ, ¼Ò¸ðǰ, ¾×¼¼¼­¸®); ÃÖÁ¾ »ç¿ë(º´¿ø ÃÖÁ¾ »ç¿ë, ÀçÅà ÀÇ·á ÃÖÁ¾ »ç¿ë, Ŭ¸®´Ð&¿Ü·¡ ¼ö¼ú ¼¾ÅÍ ÃÖÁ¾ »ç¿ë)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Infusion Therapy Devices Market to Reach US$69.5 Billion by 2030

The global market for Infusion Therapy Devices estimated at US$45.0 Billion in the year 2024, is expected to reach US$69.5 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Infusion Pumps, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$45.2 Billion by the end of the analysis period. Growth in the Consumables segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$12.3 Billion While China is Forecast to Grow at 12.0% CAGR

The Infusion Therapy Devices market in the U.S. is estimated at US$12.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$14.9 Billion by the year 2030 trailing a CAGR of 12.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Infusion Therapy Devices Market - Key Trends & Drivers Summarized

Why Are Infusion Therapy Devices Becoming Increasingly Essential Across Clinical Settings?

Infusion therapy devices are becoming an indispensable part of modern healthcare as the demand for controlled, precise, and continuous administration of fluids, medications, nutrients, and blood products increases across hospital and outpatient environments. These devices are critical in delivering intravenous therapies for a wide range of conditions including cancer, infections, dehydration, chronic pain, and autoimmune diseases. Hospitals, ambulatory surgery centers, and home care providers rely on infusion pumps, IV sets, and catheters to ensure consistent dosing and patient safety. With an aging global population and the corresponding rise in chronic illnesses such as diabetes, cardiovascular disease, and cancer, the need for long-term and home-based infusion therapy is growing rapidly. This trend is pushing healthcare systems to shift from acute inpatient care toward more flexible, patient-centered delivery models. Infusion devices also play a key role in critical care and emergency medicine, where rapid, accurate delivery of medications can mean the difference between life and death. Pediatric and neonatal units require specially designed infusion systems that accommodate low-volume, highly sensitive dosages. Furthermore, the increasing use of biologic therapies and specialty pharmaceuticals, many of which require intravenous or subcutaneous delivery over extended periods, is expanding the therapeutic scope of infusion devices. With the emergence of value-based care models and hospital readmission penalties, ensuring safe and effective outpatient infusion is also becoming a cost-containment strategy. These factors together underscore the expanding importance of infusion therapy devices as the backbone of therapeutic administration across healthcare systems worldwide.

Can Technological Innovation Improve Safety and Efficiency in Infusion Therapy?

Technological innovation is revolutionizing the design and function of infusion therapy devices, making them safer, more accurate, and easier to use for both clinicians and patients. Traditional infusion pumps have evolved into smart devices capable of real-time monitoring, data logging, and integration with hospital information systems. Modern infusion pumps now include dose error reduction systems (DERS) that help prevent incorrect programming and reduce the risk of medication errors. These smart pumps feature built-in drug libraries and alert systems that notify nurses and pharmacists of deviations from prescribed dosage parameters, thereby improving patient safety. Wireless connectivity allows for remote monitoring and automatic documentation in electronic health records, reducing the administrative burden on healthcare workers and enabling better tracking of infusion-related metrics. Portable and wearable infusion devices have also advanced significantly, offering greater mobility for patients requiring continuous therapy in home or ambulatory settings. Innovations in microfluidics and sensor integration are leading to the development of infusion systems that automatically adjust flow rates based on patient-specific variables, such as body weight or fluid balance. Battery technology improvements have extended operating times and allowed for more compact form factors. In addition, advancements in materials science are producing more durable and biocompatible catheter lines, minimizing the risk of infections and adverse reactions. Artificial intelligence is beginning to influence infusion therapy as well, with predictive algorithms helping to identify potential complications like occlusions or air-in-line incidents before they occur. These continuous improvements are enhancing not only the technical performance of infusion therapy devices but also the overall clinical workflow, enabling more efficient and personalized care.

How Do Different Medical Specialties Influence the Customization and Use of Infusion Devices?

The infusion therapy devices market is characterized by high specialization, with different medical fields requiring unique features and performance standards tailored to their specific clinical applications. In oncology, for example, infusion devices must accommodate complex chemotherapy regimens that involve precise dosing schedules and delivery of cytotoxic agents that require specialized safety features to protect healthcare personnel. In infectious disease management, especially during outbreaks or pandemics, infusion pumps must support rapid deployment and high-volume usage for the delivery of antibiotics, antivirals, or hydration solutions. Pain management protocols in surgical and palliative care often rely on patient-controlled analgesia (PCA) pumps, which allow individuals to self-administer prescribed doses of pain medication within safe parameters. In critical care and neonatal units, infusion devices must support low-volume, highly precise dosing, sometimes down to the microliter level, and must be equipped with advanced alarms and fail-safes. Cardiology units use infusion therapy for vasopressors, inotropes, and anticoagulants, all of which require real-time monitoring and reliable rate control. In home healthcare, the focus is on portability, simplicity, and intuitive interfaces, as patients and caregivers must manage therapies without direct medical supervision. Even veterinary medicine uses infusion pumps designed for animals of different sizes, underscoring the market's breadth. This clinical diversity has spurred manufacturers to develop a wide array of devices ranging from volumetric and syringe pumps to elastomeric and implantable systems. Regulatory compliance, user training, and compatibility with various infusion sets also vary depending on the medical discipline, influencing design priorities and purchasing decisions. As a result, the infusion therapy devices market has evolved into a highly segmented landscape where customization, safety, and usability remain central to product differentiation and clinical adoption.

What Is Driving the Rapid Growth of the Infusion Therapy Devices Market Worldwide?

The growth in the infusion therapy devices market is driven by several converging factors that span demographic trends, technological advancement, healthcare reform, and the rising burden of chronic disease. One of the most significant drivers is the global increase in aging populations, who are more susceptible to multiple chronic conditions requiring long-term and frequent infusion therapies. The expanding prevalence of diseases such as cancer, diabetes, autoimmune disorders, and cardiovascular conditions further amplifies the need for continuous, reliable medication administration. The global shift toward outpatient care and home-based healthcare services is encouraging the development and adoption of portable, user-friendly infusion systems, allowing patients to receive treatment without lengthy hospital stays. At the same time, hospital and clinic administrators are seeking infusion solutions that streamline workflow, reduce human error, and support electronic documentation to meet regulatory standards and improve patient outcomes. Government investments in healthcare infrastructure, especially in emerging economies, are opening new markets for infusion devices and driving volume sales. Public health emergencies such as the COVID-19 pandemic have underscored the importance of scalable and rapidly deployable infusion solutions for treating large numbers of patients in intensive care settings. Moreover, reimbursement reforms in many countries are incentivizing value-based care, where accurate medication delivery and avoidance of adverse events directly impact provider compensation. Strategic collaborations between technology firms and medical device companies are also accelerating the pace of innovation, introducing smart features that align with the broader digital transformation of healthcare. Collectively, these drivers are creating a fertile environment for rapid growth, pushing the infusion therapy devices market toward greater technological sophistication, broader accessibility, and expanded clinical utility on a global scale.

SCOPE OF STUDY:

The report analyzes the Infusion Therapy Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Infusion Pumps, Consumables, Accessories); End-Use (Hospitals End-Use, Homecare Settings End-Use, Clinics & Ambulatory Surgery Centers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â